This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Astellas Pharma ends buyout talks with Kaketsuken

( October 20, 2016, 02:02 GMT | Official Statement) -- MLex Summary: Astellas Pharma has terminated its talks with Kaketsuken, another Japanese pharmaceuticals company, over the potential purchase of its businesses, the two companies said in separate statements. Astellas said in a statement that the decision had been made in light of “the current situation and various factors.” Kaketsuken, which last year acknowledged that it had been making blood products using an unauthorized method, said that it would continue to make efforts to “drastically review” its compliance mechanism. The talks between the two companies began after the product scandal broke.  The companies' statements are attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login